Victor Mak

ORCID: 0000-0003-4689-5383
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sperm and Testicular Function
  • Reproductive Biology and Fertility
  • Gestational Trophoblastic Disease Studies
  • Prenatal Screening and Diagnostics
  • Cystic Fibrosis Research Advances
  • Reproductive Health and Technologies
  • Cancer Mechanisms and Therapy
  • Sexual Differentiation and Disorders
  • Cancer-related Molecular Pathways
  • Lymphoma Diagnosis and Treatment
  • PI3K/AKT/mTOR signaling in cancer
  • PARP inhibition in cancer therapy
  • Epigenetics and DNA Methylation
  • RNA modifications and cancer
  • Ubiquitin and proteasome pathways
  • Spinal Dysraphism and Malformations
  • Spinal Fractures and Fixation Techniques
  • interferon and immune responses
  • Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Phagocytosis and Immune Regulation
  • Ovarian cancer diagnosis and treatment
  • Spinal Cord Injury Research
  • Sarcoma Diagnosis and Treatment
  • Neonatal Respiratory Health Research
  • Protein Tyrosine Phosphatases

University of Hong Kong
2012-2025

Merck & Co., Inc., Rahway, NJ, USA (United States)
2023

Cancer Care Ontario
2017-2023

Chinese University of Hong Kong
2012-2023

Universidade Presbiteriana Mackenzie
2023

University of Toronto
1996-2015

Victor (Japan)
2010-2013

Mount Sinai Hospital
1996-2006

Hospital for Sick Children
1996-1997

SickKids Foundation
1996

YSTIC FIBROSIS (CF) IS THE most common serious autosomal recessive condition in whites, with a prevalence of approximately 1 per 2500 and carrier frequency 25. The gene responsible for CF, called the cystic fibrosis transmembrane conductance regulator (CFTR), encodes cyclic adenosine monophosphate (cAMP)dependent chloride channel found apical membrane secretory epithelial cells. Clinical features CF include chronic pulmonary obstruction infections, exocrine pancreatic insufficiency, neonatal...

10.1001/jama.281.23.2217 article EN JAMA 1999-06-16

A committee was established at the request of CUA to determine guidelines for investigation and management azoospermia. Members committee, all whom have special expertise in male infertility, were chosen from different communities across Canada. The members represent practices communities.

10.5489/cuaj.10050 article EN Canadian Urological Association Journal 2010-06-01

<h3>OBJECTIVE</h3> To examine the relation between fatigue, disease activity, damage, and quality of life measures in patients with systemic lupus erythematosus (SLE). <h3>METHODS</h3> Consecutive attending University Toronto Lupus Clinic were studied. Disease activity was assessed using SLEDAI SLAM-R damage SLICC/ACR Damage index. Fatigue measured by Severity Score (FSS) health status SF-36 questionnaire. In all cases a tender point count also performed. <h3>RESULTS</h3> 81 Their mean (SD)...

10.1136/ard.58.6.379 article EN Annals of the Rheumatic Diseases 1999-06-01

No AccessJournal of UrologyClinical Urology: Review Article1 Oct 1996The Genetics Male Infertility Victor Mak and Keith A. Jarvi MakVictor JarviKeith View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65561-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We provide an up-to-date summary the genetic aspects male infertility. Materials Methods: The literature on infertility was...

10.1016/s0022-5347(01)65561-7 article EN The Journal of Urology 1996-10-01

The 5-thymidine (5T) variant of the cystic fibrosis transmembrane conductance regulator (CFTR) intron 8 polypyrimidine tract (IVS8-T tract) is most frequent CFTR gene alteration identified in men with congenital bilateral absence vas deferens (CBAVD). This alternative splicing gives rise to two transcripts, one normal exon 9 intact and other in-frame deletion 9. That CBAVD usually have none clinical signs classical (CF) suggests less functional produced reproductive than CF-associated...

10.1093/hmg/6.12.2099 article EN Human Molecular Genetics 1997-11-01

Abstract Copy number loss of PIK3R1 (p85α) most commonly occurs in ovarian cancer among all types. Here we report that cells manifest a spectrum tumorigenic phenotypes upon knockdown . activates AKT and p110-independent JAK2/STAT3 signaling through inducing changes the phosphorylation docking protein Gab2, thereby relieving negative inhibition on promoting assembly signalosome, respectively. Additional mechanisms leading to activation include enhanced p110α kinase activity decrease PTEN...

10.1038/s41467-019-08574-7 article EN cc-by Nature Communications 2019-02-12

p85β is a regulatory subunit of the phosphoinositide 3-kinase (PI3K). Emerging evidence suggests that goes beyond its role in PI3K and functional nucleus. In this study, we discover nuclear enriched at gene loci regulates transcription contributes to oncogenic potential p85β. A multi-omics approach reveals physical interaction cooperativity between factor BCLAF1. We observe genome-wide co-occupancy BCLAF1 targets associated with transcriptional responses. Intriguingly, targetome includes...

10.1038/s41467-025-56532-3 article EN cc-by-nc-nd Nature Communications 2025-02-27

Gestational trophoblastic disease (GTD) includes frankly malignant choriocarcinoma (CCA) and placental site tumor potentially hydatidiform mole. p21-Activated kinase (PAK) 4 promotes cell motility. This study investigated the role of PAK4 in pathogenesis GTD. messenger RNA protein expressions clinical samples lines normal placentas GTD were determined by quantitative real-time polymerase chain reaction western blot, respectively. The effects human chorionic gonadotropin (hCG)...

10.1093/carcin/bgr033 article EN Carcinogenesis 2011-02-16

A committee was established at the request of Canadian Urological Association to develop guidelines for investigation and management azoospermia.Members committee, all whom have special expertise in male

10.5489/cuaj.3209 article EN Canadian Urological Association Journal 2015-08-10

Abstract PIK3R2 encodes the p85β regulatory subunit of phosphatidylinositol 3-kinase and is frequently amplified in cancers. The signaling mechanism therapeutic implication are poorly understood. Here we report that upregulates protein level receptor tyrosine kinase AXL to induce oncogenic ovarian cancer. activates p110 activity AKT-independent PDK1/SGK3 promote tumorigenic phenotypes, which all abolished upon inhibition AXL. At molecular level, alters phosphorylation TRIM2 (an E3 ligase)...

10.1038/s41467-020-16061-7 article EN cc-by Nature Communications 2020-05-08

BACKGROUND To measure the clinical impact of pretreatment fludeoxyglucose positron emission tomography/computed tomography (PET/CT) on staging and management apparent limited stage indolent lymphoma being considered for curative radiation therapy. METHODS We conducted a prospective multicenter registry study that included 197 patients accrued between May 1, 2012, December 31, 2015. Pre‐PET/CT stage, determined by CT data, was documented. If pre‐PET/CT indeterminate, assigned to patient...

10.1002/cncr.30672 article EN Cancer 2017-03-13

For these priority topics, we performed a critical evaluation of the literature using Evidence to Decision (EtD) GRADE framework arrive at transparent evidence-based recommendations

10.5489/cuaj.8445 article EN Canadian Urological Association Journal 2023-05-30

It has been proposed that the gene responsible for cystic fibrosis, called fibrosis transmembrane conductance regulator (CFTR) gene, may play an important role in process of spermatogenesis. A group azoospermic men with primary testicular failure underwent CFTR mutation analysis, including assessment intron 8 polythymidine tract (IVS8-T tract). An association was not found between mutations or 5T variant IVS8-T and phenotype. This finding suggests does a significant aetiopathogenesis...

10.1093/humrep/15.2.436 article EN Human Reproduction 2000-02-01

Purpose To determine the relationship of PET/CT staging to management and outcomes participants with apparent limited-stage (LS) Hodgkin lymphoma (HL) or aggressive non-HL (ANHL) treated curative intent. Materials Methods This prospective multicenter registry included 850 (467 men 383 women; median age, 54.1 years) from nine centers who had LS HL ANHL on basis clinical data CT, equivocal CT for advanced stage, were considered curative-intent first-line therapy. Participants recruited between...

10.1148/radiol.2018181519 article EN Radiology 2018-12-04

Gestational choriocarcinoma is a malignant tumor derived from placental trophoblast and the most aggressive member of gestational trophoblastic disease (GTD). Apoptosis-stimulating protein p53-2 (ASPP2) ASPP family that transactivates p53 thereby functions as suppressor. In this study, expression profile ASPP2 in was examined comparison with normal placentas hydatidiform moles, latter being type GTD carries potential. Downregulation messenger RNA demonstrated by quantitative PCR...

10.1093/carcin/bgt161 article EN Carcinogenesis 2013-05-13

EGFR signaling promotes ovarian cancer tumorigenesis, and high expression correlates with poor prognosis. However, inhibitors alone have demonstrated limited clinical benefit for patients, owing partly to tumor resistance the lack of predictive biomarkers. Cotargeting PI3K pathway has been previously shown yield synergistic antitumor effects in cancer. Therefore, we reasoned that may affect cellular response inhibition. In this study, revealed isoform-specific on sensitivity cells inhibitor...

10.1016/j.neo.2021.05.009 article EN cc-by-nc-nd Neoplasia 2021-06-16

We evaluated the role of magnetic resonance imaging (MRI) lumbosacral spinal cord in patients with voiding complaints and abnormal urodynamic findings but normal neurological lower spine examinations.We studied 17 women 13 men to 50 years old (mean age 32.2) who presented complaints. All had a completely examination no evidence prostatic enlargement. Of 30 18 incontinence (17 urge, 1 stress urge), 9 frequency urgency alone, 3 urinary retention. Seven persistent enuresis (2 primary 5...

10.1016/s0022-5347(01)65606-4 article EN The Journal of Urology 1996-10-01
Coming Soon ...